Currently,detecting SARS-CoV-2 RNAs is a standard approach for COVID-19 diagnosis.However,there is an urgent need for reliable and rapid serological diagnostic methods to screen SARS-CoV-2-infected people including th...Currently,detecting SARS-CoV-2 RNAs is a standard approach for COVID-19 diagnosis.However,there is an urgent need for reliable and rapid serological diagnostic methods to screen SARS-CoV-2-infected people including those who do not have overt symptoms.Most emerging studies described serological tests based on detection of SARS-CoV-2-specific IgM and IgG.1–4 Although detection of SARS-CoV-2-specific IgA in serum has been reported in few papers,5,6 analyses of IgA levels in a larger number of COVID-19 patients are still lacking.展开更多
Identification of a suitable nonhuman primate(NHP)model of COVID-19 remains challenging.Here,we characterized severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection in three NHP species:Old World monkeys...Identification of a suitable nonhuman primate(NHP)model of COVID-19 remains challenging.Here,we characterized severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection in three NHP species:Old World monkeys Macaca mulatta(M.mulatta)and Macaca fascicularis(M.fascicularis)and New World monkey Callithrix jacchus(C.jacchus).Infected M.mulatta and M.fascicularis showed abnormal chest radiographs,an increased body temperature and a decreased body weight.Viral genomes were detected in swab and blood samples from all animals.Viral load was detected in the pulmonary tissues of M.mulatta and M.fascicularis but not C.jacchus.Furthermore,among the three animal species,M.mulatta showed the strongest response to SARS-CoV-2,including increased inflammatory cytokine expression and pathological changes in the pulmonary tissues.Collectively,these data revealed the different susceptibilities of Old World and New World monkeys to SARS-CoV-2 and identified M.mulatta as the most suitable for modeling COVID-19.展开更多
Starting from December 2019,Wuhan,China,encountered the first outbreak of coronavirus disease 2019(COVID-19)(1-2).The epidemic was successfully suppressed by strict containment so that the number of infected people wa...Starting from December 2019,Wuhan,China,encountered the first outbreak of coronavirus disease 2019(COVID-19)(1-2).The epidemic was successfully suppressed by strict containment so that the number of infected people was reduced to 0 on April 8,2020(3–4).After that,China experienced roughly 3 dozen outbreaks with local transmission caused by imported severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).展开更多
A very recent work published in Advanced Science by our group reveals that 2′-deoxy-2′-β-fluoro-4′-azidocytidine(Azvudine,FNC),a clinical candidate originally developed for HIV treatment,has entered clinical trial...A very recent work published in Advanced Science by our group reveals that 2′-deoxy-2′-β-fluoro-4′-azidocytidine(Azvudine,FNC),a clinical candidate originally developed for HIV treatment,has entered clinical trial in China for evaluating its efficacy and safety(ChiCTR2000029853),showing promise for treating novel coronavirus disease 2019(COVID-19).1 This work suggests that nucleoside-based antivirus agents could be repurposed for COVID-19 treatment.展开更多
On January 2,2021,2 cases of coronavirus disease 2019(COVID-19)were identified in 2 cities of Hebei Province,and genomic sequencing suggested that the cases likely resulted from the same origin.The first case(Patient ...On January 2,2021,2 cases of coronavirus disease 2019(COVID-19)were identified in 2 cities of Hebei Province,and genomic sequencing suggested that the cases likely resulted from the same origin.The first case(Patient A)was identified as positive at 12∶18 in Shijiazhuang City,the capital of Hebei Province,and the second case(Patient B)was identified as positive at 21∶00 in Xingtai City.展开更多
Summary What is already known about this topic?COVID-19 vaccines are important tools to protect populations from severe disease and death.What is added by this report?Among persons aged≥60 years in Hong Kong,49%,had ...Summary What is already known about this topic?COVID-19 vaccines are important tools to protect populations from severe disease and death.What is added by this report?Among persons aged≥60 years in Hong Kong,49%,had received≥2 doses of a COVID-19 vaccine,and vaccination coverage declined with age.During January-March 2022,reported COVID-19-associated deaths rose rapidly in Hong Kong.Among these deaths,96%occurred in persons aged≥60 years;within this age group,the risk for death was 20 times lower among those who were fully vaccinated compared with those who were unvaccinated.展开更多
Before the coronavirus disease 2019(COVID-19)outbreak on July 16,2020,no new COVID-19 cases were reported in Urumqi City of Xinjiang for 150 consecutive days.During this outbreak,826 confirmed COVID-19 cases have been...Before the coronavirus disease 2019(COVID-19)outbreak on July 16,2020,no new COVID-19 cases were reported in Urumqi City of Xinjiang for 150 consecutive days.During this outbreak,826 confirmed COVID-19 cases have been reported in Urumqi.The phylogenetic characteristics of COVID-19 virus from clinical specimens of the initial 4 cases in the Urumqi outbreak were sequenced.展开更多
At the time of writing,the coronavirus disease(COVID-19)has affected 212 countries and territories across the globe.According to the world health organization(WHO),a total number of 4,735,622 confirmed cases,including...At the time of writing,the coronavirus disease(COVID-19)has affected 212 countries and territories across the globe.According to the world health organization(WHO),a total number of 4,735,622 confirmed cases,including 316,289 deaths was reported[1].In the fight against COVID-19,nurses,doctors,and other healthcare workers are in the front line of the battle bearing the higher risk of infection[2].The International Council of Nurses(ICN)gathered further information to suggest that more than 90,000 healthcare workers have been infected worldwide[3].Personal protective equipment(PPE)shortage is one of the key factors increasing the infection risk for the medical staffs.Therefore,finding alternative ways to lower the infection risk has become an urgent problem to be solved.展开更多
Introduction: Covid-19 is a systemic disease that can spread to all systems. Among the gastrointestinal manifestations, pancreatic involvement can have a major prognostic impact. We report 3 acute pancreatitis cases o...Introduction: Covid-19 is a systemic disease that can spread to all systems. Among the gastrointestinal manifestations, pancreatic involvement can have a major prognostic impact. We report 3 acute pancreatitis cases occurring during Covid-19, in Dakar. Case 1: 65-year-old woman who presented with intense atypical epigastric pain. Physical examination revealed obesity, high blood pressure and abdominal tenderness. Biological tests found increase CRP (134 mg/l) and lipasemia (312 UI/l). Abdominal CT scan showed findings of Balthazar grade C acute pancreatitis. RT-PCR for SARS CoV 2 RT-PCR was positive. The outcome was favorable. Case 2: 56-year-old woman patient with history of nephroangiosclerosis who presented with dyspnea, cough, fever and moderate epigastric pain. Physical examination revealed epigastric tenderness, high blood pressure, anuria. Biological testing, noted increase CRP (96 mg/l), lipasemia (793 UI/l), creatinine (227 mg/l) and urea (3.84 g/l). Abdominal CT scan showed acute edematous pancreatitis findings. SARS CoV 2 RT PCR was positive. The outcome was favorable. Case 3: 27-year-old man who presented with physical asthenia, headache, and epigastric pain. Physical examination found epigastric tenderness. Elevated CRP level was of 102 mg/l and lipasemia level was of 427 UI/l (7N). Abdominal CT scan showed acute edematous pancreatitis findings. SARS CoV 2 RT PCR was positive. The outcome was favorable. Conclusion: Acute pancreatitis can occur during Covid-19 infection. However, the imputability to the Covid-19 disease necessitates to rule out the most common causes.展开更多
Recently,three groups evaluated the effects of monoclonal antibodies,convalescent serum,and vaccines on Delta variant,^(1-3)which leads to concerns about the effectiveness of current vaccines to the upcoming SARS-CoV-...Recently,three groups evaluated the effects of monoclonal antibodies,convalescent serum,and vaccines on Delta variant,^(1-3)which leads to concerns about the effectiveness of current vaccines to the upcoming SARS-CoV-2 variants.The World Health Organization(WHO)has designated SARS-CoV-2 variants Alpha(B.1.1.7),Beta(B.1.351),Gamma(P.1),and Delta(B.1.617.2)as Variants of Concern(VOC),among which Delta variant with remarkable transmission and immune escape ability has attracted great attentions.展开更多
近日,上海森薇国际贸易有限公司携手西班牙巴斯克厨艺学院、桃乐丝中国,在北京福楼·罗蒂(RÔTI by FLO)花园举办了一场别开生面的路演活动,通过感官探索伊比利亚火腿的精彩世界。上海森薇国际贸易有限公司是西班牙ALTA EXPRESS...近日,上海森薇国际贸易有限公司携手西班牙巴斯克厨艺学院、桃乐丝中国,在北京福楼·罗蒂(RÔTI by FLO)花园举办了一场别开生面的路演活动,通过感官探索伊比利亚火腿的精彩世界。上海森薇国际贸易有限公司是西班牙ALTA EXPRESSION COVAP(简称AX COVAP)伊比利亚火腿在中国的独家代理,该品牌亚洲和非洲区域销售总监Pedro Salado先生出席了活动。展开更多
The coronavirus disease 2019(COVID-19)outbreak in late 2019 significantly impacted global health.The virus’s rapid spread,with its long incubation period and high infection level,caused substantial disruption to regu...The coronavirus disease 2019(COVID-19)outbreak in late 2019 significantly impacted global health.The virus’s rapid spread,with its long incubation period and high infection level,caused substantial disruption to regular social frameworks,production,and lifestyles^([1]).COVID-19 is primarily transmitted through close contact,long-range contaminants,and airborne routes.展开更多
In 2021,China’s domestically produced coronavirus disease 2019(COVID-19)vaccines received approval from regulatory bodies and were administered worldwide.Due to a low number of infections within China during that per...In 2021,China’s domestically produced coronavirus disease 2019(COVID-19)vaccines received approval from regulatory bodies and were administered worldwide.Due to a low number of infections within China during that period,it became imperative to evaluate the vaccines’real-world effectiveness through international studies.To facilitate this,China CDC launched the COVID-19 Vaccines Evaluation Program(COVEP).This program formed research collaboration agreements with health institutes across five World Health Organization regions,addressing key questions about vaccine performance through ten cooperative agreements.The findings from COVEP projects reinforced confidence,both domestically and globally,in the effectiveness of the vaccines produced in China.Moreover,the outcomes observed internationally were frequently mirrored by later studies conducted within China.COVEP thus pioneered a novel approach for fostering cross-national research collaborations,addressing significant public health issues and exemplifying a framework for international cooperation.This approach is in line with the strategic objectives and other development efforts of China CDC’s national disease control and prevention initiatives.展开更多
Dear Editor,Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus-2(SARS-CoV-2),has rapidly swept through the worldwide,with more than 3 million confirmed cases.Until now,no vaccine...Dear Editor,Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus-2(SARS-CoV-2),has rapidly swept through the worldwide,with more than 3 million confirmed cases.Until now,no vaccine or effective therapeutic measures are provided to prevent the SARS-CoV-2 infection.Existing medicines have some strong advantages on pharmacokinetics,known side effects,safety and dosing regimens.1 Although remdesivir and chloroquine could effectively inhibit the replication of SARS-CoV-2 in vitro,2 no medicine candidates have been evaluated in vivo by using animal models with SARS-CoV-2 infection.展开更多
What is already known about this topic?The significant disparities in global coronavirus disease 2019(COVID-19)vaccine coverage hamper the pace of epidemic control.There is a need to better understand the factors cont...What is already known about this topic?The significant disparities in global coronavirus disease 2019(COVID-19)vaccine coverage hamper the pace of epidemic control.There is a need to better understand the factors contributing to disparities in COVID-19 vaccination rates across countries.What is added by this report?This report revealed significant associations between vaccination coverage and various country-level indicators.Better pandemic preparedness,higher levels of trust,and a lower proportion of young population aged 0–14 were strongly correlated with higher COVID-19 vaccination coverage.What are the implications for public health practices?Our findings emphasize the need for enhanced pandemic preparedness and governance,coupled with building trust in government and healthcare systems.It also needs to address the hesitancy of vaccinating children and adolescents aged 0–14 as the vaccination campaign progresses.展开更多
基金We acknowledge funding support from the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB29030104)National Natural Science Foundation of China(Grant Nos.:31870731 and U1732109)+2 种基金the Fundamental Research Funds for the Central Universities(WK2070000108)a COVID-19 special task grant supported by Chinese Academy of Science Clinical Research Hospital(Hefei)(YD2070002017 and YD2070002001)the new medical science fund of USTC(WK2070000130).
文摘Currently,detecting SARS-CoV-2 RNAs is a standard approach for COVID-19 diagnosis.However,there is an urgent need for reliable and rapid serological diagnostic methods to screen SARS-CoV-2-infected people including those who do not have overt symptoms.Most emerging studies described serological tests based on detection of SARS-CoV-2-specific IgM and IgG.1–4 Although detection of SARS-CoV-2-specific IgA in serum has been reported in few papers,5,6 analyses of IgA levels in a larger number of COVID-19 patients are still lacking.
基金supported by the National Research and Development Project of China(2020YFC0841100,2020YFC0846400,and 2020YFA0707600)CAMS Innovation Fund for Medical Sciences(2016-I2M-2-006 and 2020-I2M-CoV19-012)+1 种基金the Talents Project of Yunnan Province(2017HB068)the Special Funds for High-level Health and Family Planning Technical Personnel training of Yunnan Province(D-201653).
文摘Identification of a suitable nonhuman primate(NHP)model of COVID-19 remains challenging.Here,we characterized severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection in three NHP species:Old World monkeys Macaca mulatta(M.mulatta)and Macaca fascicularis(M.fascicularis)and New World monkey Callithrix jacchus(C.jacchus).Infected M.mulatta and M.fascicularis showed abnormal chest radiographs,an increased body temperature and a decreased body weight.Viral genomes were detected in swab and blood samples from all animals.Viral load was detected in the pulmonary tissues of M.mulatta and M.fascicularis but not C.jacchus.Furthermore,among the three animal species,M.mulatta showed the strongest response to SARS-CoV-2,including increased inflammatory cytokine expression and pathological changes in the pulmonary tissues.Collectively,these data revealed the different susceptibilities of Old World and New World monkeys to SARS-CoV-2 and identified M.mulatta as the most suitable for modeling COVID-19.
基金Supported by the National Natural Science Foundation(grant number 71934002)of the People’s Republic of China.
文摘Starting from December 2019,Wuhan,China,encountered the first outbreak of coronavirus disease 2019(COVID-19)(1-2).The epidemic was successfully suppressed by strict containment so that the number of infected people was reduced to 0 on April 8,2020(3–4).After that,China experienced roughly 3 dozen outbreaks with local transmission caused by imported severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).
基金supported by Henan Province Novel Coronavirus Control and Prevention Emergency Science and Technology Tackling Key Project(No.201100311500)National Natural Science Foundation of China(No.U1804283).
文摘A very recent work published in Advanced Science by our group reveals that 2′-deoxy-2′-β-fluoro-4′-azidocytidine(Azvudine,FNC),a clinical candidate originally developed for HIV treatment,has entered clinical trial in China for evaluating its efficacy and safety(ChiCTR2000029853),showing promise for treating novel coronavirus disease 2019(COVID-19).1 This work suggests that nucleoside-based antivirus agents could be repurposed for COVID-19 treatment.
文摘On January 2,2021,2 cases of coronavirus disease 2019(COVID-19)were identified in 2 cities of Hebei Province,and genomic sequencing suggested that the cases likely resulted from the same origin.The first case(Patient A)was identified as positive at 12∶18 in Shijiazhuang City,the capital of Hebei Province,and the second case(Patient B)was identified as positive at 21∶00 in Xingtai City.
文摘Summary What is already known about this topic?COVID-19 vaccines are important tools to protect populations from severe disease and death.What is added by this report?Among persons aged≥60 years in Hong Kong,49%,had received≥2 doses of a COVID-19 vaccine,and vaccination coverage declined with age.During January-March 2022,reported COVID-19-associated deaths rose rapidly in Hong Kong.Among these deaths,96%occurred in persons aged≥60 years;within this age group,the risk for death was 20 times lower among those who were fully vaccinated compared with those who were unvaccinated.
基金supported by the National Key Research and Development Program of China(Program No.2018YFC1200305)National Science and Technology Major Project of China(Project No.2017ZX10104001,2018ZX10102001,2018ZX10711001,2018ZX10713002).
文摘Before the coronavirus disease 2019(COVID-19)outbreak on July 16,2020,no new COVID-19 cases were reported in Urumqi City of Xinjiang for 150 consecutive days.During this outbreak,826 confirmed COVID-19 cases have been reported in Urumqi.The phylogenetic characteristics of COVID-19 virus from clinical specimens of the initial 4 cases in the Urumqi outbreak were sequenced.
基金supported by the National Natural Science Foundation of China (51975513)the Natural Science Foundation of Zhejiang Province (LR20E050003)+4 种基金the Zhejiang University Special Scientific Research Fund for COVID-19 Prevention and Control (2020XGZX017)China’s Thousand Talents Plan Young Professionals Program, Major Research Plan (51890884)State Key Laboratory of Fluid Power and Mechatronic Systems (SKLo FP_ZZ_2002)Science Fund for Creative Research Groups (51821093)Robotics Institute of Zhejiang University (K18-508116-008-03)
文摘At the time of writing,the coronavirus disease(COVID-19)has affected 212 countries and territories across the globe.According to the world health organization(WHO),a total number of 4,735,622 confirmed cases,including 316,289 deaths was reported[1].In the fight against COVID-19,nurses,doctors,and other healthcare workers are in the front line of the battle bearing the higher risk of infection[2].The International Council of Nurses(ICN)gathered further information to suggest that more than 90,000 healthcare workers have been infected worldwide[3].Personal protective equipment(PPE)shortage is one of the key factors increasing the infection risk for the medical staffs.Therefore,finding alternative ways to lower the infection risk has become an urgent problem to be solved.
文摘Introduction: Covid-19 is a systemic disease that can spread to all systems. Among the gastrointestinal manifestations, pancreatic involvement can have a major prognostic impact. We report 3 acute pancreatitis cases occurring during Covid-19, in Dakar. Case 1: 65-year-old woman who presented with intense atypical epigastric pain. Physical examination revealed obesity, high blood pressure and abdominal tenderness. Biological tests found increase CRP (134 mg/l) and lipasemia (312 UI/l). Abdominal CT scan showed findings of Balthazar grade C acute pancreatitis. RT-PCR for SARS CoV 2 RT-PCR was positive. The outcome was favorable. Case 2: 56-year-old woman patient with history of nephroangiosclerosis who presented with dyspnea, cough, fever and moderate epigastric pain. Physical examination revealed epigastric tenderness, high blood pressure, anuria. Biological testing, noted increase CRP (96 mg/l), lipasemia (793 UI/l), creatinine (227 mg/l) and urea (3.84 g/l). Abdominal CT scan showed acute edematous pancreatitis findings. SARS CoV 2 RT PCR was positive. The outcome was favorable. Case 3: 27-year-old man who presented with physical asthenia, headache, and epigastric pain. Physical examination found epigastric tenderness. Elevated CRP level was of 102 mg/l and lipasemia level was of 427 UI/l (7N). Abdominal CT scan showed acute edematous pancreatitis findings. SARS CoV 2 RT PCR was positive. The outcome was favorable. Conclusion: Acute pancreatitis can occur during Covid-19 infection. However, the imputability to the Covid-19 disease necessitates to rule out the most common causes.
基金Huahao Fan declares grants from National Key Research and Development Program of China(grant No.2020YFA0712102)Fundamental Research Funds for Central Universities(grant No.BUCTZY2022)H&H Global Research and Technology Center(grant No.H2021028).
文摘Recently,three groups evaluated the effects of monoclonal antibodies,convalescent serum,and vaccines on Delta variant,^(1-3)which leads to concerns about the effectiveness of current vaccines to the upcoming SARS-CoV-2 variants.The World Health Organization(WHO)has designated SARS-CoV-2 variants Alpha(B.1.1.7),Beta(B.1.351),Gamma(P.1),and Delta(B.1.617.2)as Variants of Concern(VOC),among which Delta variant with remarkable transmission and immune escape ability has attracted great attentions.
基金supported by grants from the National Natural Science Foundation of China(Grant Nos.42375177,41975141)the Natural Science Foundation of Gansu(Grant No.23JRRA1079)。
文摘The coronavirus disease 2019(COVID-19)outbreak in late 2019 significantly impacted global health.The virus’s rapid spread,with its long incubation period and high infection level,caused substantial disruption to regular social frameworks,production,and lifestyles^([1]).COVID-19 is primarily transmitted through close contact,long-range contaminants,and airborne routes.
基金supported by the Chinese Center for Disease Control and Prevention through the COVID-19 Vaccines Evaluation Program(COVEP).
文摘In 2021,China’s domestically produced coronavirus disease 2019(COVID-19)vaccines received approval from regulatory bodies and were administered worldwide.Due to a low number of infections within China during that period,it became imperative to evaluate the vaccines’real-world effectiveness through international studies.To facilitate this,China CDC launched the COVID-19 Vaccines Evaluation Program(COVEP).This program formed research collaboration agreements with health institutes across five World Health Organization regions,addressing key questions about vaccine performance through ten cooperative agreements.The findings from COVEP projects reinforced confidence,both domestically and globally,in the effectiveness of the vaccines produced in China.Moreover,the outcomes observed internationally were frequently mirrored by later studies conducted within China.COVEP thus pioneered a novel approach for fostering cross-national research collaborations,addressing significant public health issues and exemplifying a framework for international cooperation.This approach is in line with the strategic objectives and other development efforts of China CDC’s national disease control and prevention initiatives.
基金supported by the National Key Research and Development Project of China(Grant No.2016YFD0500304)CAMS initiative for Innovative Medicine of China(Grant No.2016-I2M-2-006)+1 种基金National Mega projects of China for Major Infectious Diseases(Grant Nos.2017ZX10304402,2018ZX10301403)Fundamental Research Funds for CAMS of China(Grant No.2020HY320001).
文摘Dear Editor,Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus-2(SARS-CoV-2),has rapidly swept through the worldwide,with more than 3 million confirmed cases.Until now,no vaccine or effective therapeutic measures are provided to prevent the SARS-CoV-2 infection.Existing medicines have some strong advantages on pharmacokinetics,known side effects,safety and dosing regimens.1 Although remdesivir and chloroquine could effectively inhibit the replication of SARS-CoV-2 in vitro,2 no medicine candidates have been evaluated in vivo by using animal models with SARS-CoV-2 infection.
基金Supported by the National Natural Science Foundation of China[No.71874034(Dr Hou)]the Soft Science Research Project of Shanghai“Science and Technology Innovation Action Plan”[No.22692107600(Dr Hou)].
文摘What is already known about this topic?The significant disparities in global coronavirus disease 2019(COVID-19)vaccine coverage hamper the pace of epidemic control.There is a need to better understand the factors contributing to disparities in COVID-19 vaccination rates across countries.What is added by this report?This report revealed significant associations between vaccination coverage and various country-level indicators.Better pandemic preparedness,higher levels of trust,and a lower proportion of young population aged 0–14 were strongly correlated with higher COVID-19 vaccination coverage.What are the implications for public health practices?Our findings emphasize the need for enhanced pandemic preparedness and governance,coupled with building trust in government and healthcare systems.It also needs to address the hesitancy of vaccinating children and adolescents aged 0–14 as the vaccination campaign progresses.
